Zentalis Pharmaceuticals

Today we’re excited to report our full year 2024 results and operational highlights. We’ve entered 2025 with strong momentum and a sharp focus. We believe the foundation is in place to deliver on our mission to bring azenosertib to ovarian cancer patients who urgently need new treatment options. Key Release Highlights: - Encouraging data across three azenosertib studies in cyclin E1+ platinum-resistant ovarian cancer (PROC), consistently showing >30% ORR and a manageable safety profile - Received Fast Track Designation from the FDA for azenosertib in Cyclin E1+ PROC patients - Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 - Strengthened our leadership team and Board to support focused execution Read more in the full release: https://lnkd.in/ezkA2aZ4

This past weekend we shared updated clinical data from our ongoing DENALI Part 1b trial of azenosertib in platinum-resistant ovarian cancer (PROC) at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer. Key Highlights: ?? Median duration of response (mDOR) updated to 6.3 months ?? Continued objective response rate (ORR) of ~35% in response-evaluable patients with Cyclin E1+ PROC ?? Safety profile consistent with prior data ?? DENALI Part 2 on track to begin 1H 2025, with topline registration-intent data expected by year-end 2026 ?? New preclinical data show synergistic effects of azenosertib + microtubule inhibitor-based ADCs, reinforcing its potential as a combination therapy We’re encouraged by these findings and remain committed to advancing science with patients at the center, working to bring new, targeted therapies to women facing advanced ovarian cancer. Read more in the full press release: https://lnkd.in/eSxUaAEh Check out the oral presentation and poster: https://lnkd.in/ec3DAGVH #SGO2025 #SGOMtg #OvarianCancer

Will you be at this week's Champions Oncology, Inc. 5th Annual Translational Oncology Symposium on 2/20? If so, don't miss a talk from Zentalis Senior Scientist Dr. Xiao (Joanna) G., titled "The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Effects in Combination With Topoisomerase 1 Inhibitor Based Antibody Drug Conjugates." Read more about the conference and check out the full agenda here. We're looking forward to a great day full of insights and perspectives!??https://lnkd.in/gdC9s7Fq

We're looking forward to attending this week's 5th Annual Translational Oncology Symposium in La Jolla! If you're attending as well, be sure to check out Xiao (Joanna) G.'s talk at 10:30am, titled "The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Effects in Combination With Topoisomerase 1 Inhibitor Based Antibody Drug Conjugates."

A reminder that Zentalis will be hosting a virtual corporate presentation this Wednesday at 8:00AM EST! Tune in for updated azenosertib clinical data as well as insights into our regulatory and development?plans, including a registration-intent study. Register through this link:?https://lnkd.in/eRNqZhUM Can't make it? A recording will also be available following the presentation.

Happy 2025! As the new year kicks off, we’re excited to share several updates. ? First, we're thrilled to announce that the FDA has granted Fast Track Designation to our lead candidate, azenosertib, for the treatment of Cyclin E1 positive patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer (PROC). This designation highlights the significant unmet medical need in this patient population and brings us one step closer to delivering a potential new treatment option. ?? In addition, our recent publication in npj Precision Oncology showcases how Cyclin E1/CDK2 activation can predict sensitivity to azenosertib. These findings reinforce the importance of our?biomarker-driven clinical strategy. ?? Last but not least, we’re holding a virtual corporate event on January 29, 2025, at 8:00 AM ET where we'll share: ?? Updated azenosertib clinical data ?? Insights into our regulatory and development plans, including a registration-intent study We’re excited to continue advancing azenosertib and driving innovation in oncology. Stay tuned for updates and registration details for the event on our website: www.zentalis.com. Read the full press release: https://lnkd.in/ej5Wieay

Earlier this week we shared that the FDA has lifted the partial clinical hold on our azenosertib studies. Read the full release here: https://lnkd.in/ed4SgUdp

We’ve landed in Barcelona! If you’re at #ESMO24, we welcome you to stop by our poster and say hello to Associate Director?Jianhui Ma, who will be sharing new preclinical data on azenosertib in combination with topoisomerase I inhibitor-based ADCs. https://lnkd.in/e5pWwpvm

We're thrilled to announce that Dr. Huili Zhu is the recipient of the 2024 Zentalis Women Who Conquer Cancer Young Investigator Award. The Young Investigator Award, led by Conquer Cancer, the ASCO Foundation, provides funding to the next generation of clinical oncology investigators, helping them transition from a fellowship program to a faculty appointment. Zentalis is proud to join other companies, organizations, and individuals in helping support this important program. Dr. Zhu is currently a hematology and oncology fellow at Baylor College of Medicine focusing on gastrointestinal oncology.?Her funded project, with mentorship from Dr. Jason Mills and Dr. Ramon Jin, will investigate the role of esophageal myofibroblasts in Barrett's Esophagus and Esophageal Adenocarcinoma. Read more in this latest press release: https://lnkd.in/eZHU-RNr

Did you know that May is Oncology Nursing Month? We’d like to shine a spotlight on the incredible dedication and compassion of oncology nurses, who play a pivotal role in helping cancer patients and their families. They not only provide medical expertise, but also unwavering support, comfort, and advocacy throughout every step of the journey. From administering treatments to offering a listening ear, their impact goes far beyond the hospital walls. To all the oncology nurses out there, thank you for all that you do. Your work does not go unnoticed, and your impact is immeasurable. #OncologyNursingMonth #HealthcareHeroes